分组1 - 美国参议员伯尼·桑德斯宣布默克和强生公司的CEO自愿同意在即将举行的参议院听证会上作证[2] - 参议院卫生、教育、劳工和养老金委员会的听证会定于东部时间2月8日上午10点举行，委员会计划要求J&J CEO Joaquin Duato和默克CEO Robert Davis作证[3] - 委员会将要求每位执行官就为何他们的公司在美国收取的药品价格远高于其他国家提供证词[5] - 三家公司生产的一些最昂贵的药物将受到第一轮医疗保险药品价格谈判的影响[6] - 三家公司都在起诉以阻止这些谈判，这些谈判将确定2026年生效的新价格[7] - 桑德斯希望这些制药公司的CEO能认真审视这些令人难以置信的价格差异，并与委员会合作，大幅降低他们向美国人收取这些和其他处方药的价格[8] 分组2 - 默克发言人表示相信这将是一次有益的听证会，旨在增进委员会对制药行业的理解，并找到面向患者挑战的常识性解决方案[9] - 委员会拒绝了公司提出的让其美国总裁作为证人的建议，认为CEO更适合回答有关药品定价的问题[10] - 强生公司尚未对置评请求做出回应[11]

Johnson & Johnson (JNJ) reported fourth-quarter and full-year 2024 results on Jan 23. The drug and medical devices giant beat the Zacks Consensus Estimate for both earnings as well as sales in the fourth quarter.In August, J&J completely separated its Consumer Health business into a newly listed company called Kenvue (KVUE) , which now operates as a separate and fully independent company.After completion of the exchange offer, J&J now has a 9.5% stake (approximately 180 million shares) in Kenvue’s common st ...

Buying dividend-paying stocks to hold for long periods is a relatively simple method for building wealth. That said, picking stocks most likely to maintain and raise their dividend payouts isn't always so straightforward.Johnson & Johnson (JNJ -0.53%) and Verizon Communications (VZ -2.25%) are two legendary dividend payers that recently announced results from the last three months of 2023. Let's look at their performances in light of their competitive advantages to see which is likely to deliver more divide ...

One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate. Several years ago Deutsche Bank (NYSE:DB) published a study showing that over the past century, stocks beat out gold by 5.6% per year, housing prices by 6.6%, Treasuries by 6.8%, and oil by 8.4% per year.And among the best stocks to buy have been dividend stocks. Over the past 100 years, they’ve outperformed non-divid ...

Sundry Photography Johnson & Johnson (NYSE:JNJ) reported Q4 earnings on January 23 that exceeded expectations, reaffirming guidance for FY24. The company recently spun off its consumer health subsidiary, Kenvue (KVUE), in 2023, redirecting its focus toward pharmaceuticals and medical devices. I am initiating coverage with a 'Buy' rating and a fair value target of $180 per share. 5-7% Growth in their Pharma Business JNJ stands as the second-largest pharmaceutical company globally, presenting a diverse po ...

OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its role in the opioid addiction crisis.“They knew what the harm was. They did it anyway,” Attorney General Bob Ferguson told reporters Wednesday.The attorney general’s announcement came as opioid overdose deaths more than doubled from 2019 to 2022, with 2,048 deaths recorded in 2022, according to the most recent ...

销售情况 - 强生公司2023年第四季度总销售额为214亿美元，较2022年同期增长7.3%[1] - 制药部门销售额达137.2亿美元，较去年同期增长4.2%，不包括不太受欢迎的COVID疫苗销售额，制药部门收入为136.8亿美元[5] - 医疗器械部门销售额达76.7亿美元，较2022年第四季度增长13.3%，主要受益于收购心血管医疗技术公司Abiomed[10] - 公司2023年第四季度销售增长7.3%，运营增长7.2%，调整后运营增长5.7%[13] 财务状况 - 公司披露净收入为41.3亿美元，较去年同期有所增长[2] - 公司确认2024年的指导预期，预计运营销售增长5%至6%，调整后运营每股收益在10.55至10.75美元之间[15] 业务发展 - 强生公司重点转向制药和医疗器械部门作为增长的主要驱动力[4] - 制药部门的增长主要受到多发性骨髓瘤药物Darzalex和前列腺癌药物Erleada等肿瘤治疗药物销售的推动[7] - 公司计划在2030年之前推出20多种新疗法，其中超过10种有望在销售高峰年实现50亿美元以上的销售额，包括有前景的癌症治疗药物Talvey和Tecvayli[17]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California.Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go t ...

2024年潜在批准的美国/欧盟产品 - OPSUMIT、SIMPONI、EDURANT[1] 2024年计划提交的美国/欧盟产品 - OPSUMIT、UPTRAVI、DARZALEX[1] 2024年潜在的临床数据 - 针对多发性骨髓瘤、HIV、非小细胞肺癌[1] 2023年潜在批准的美国/欧盟产品 - AKEEGA和TALVEY[8] 2023年计划提交的美国/欧盟产品 - CARVYKTI和BALVERSA[8] 2023年潜在临床数据 - RIS/gemcitabine plus cetrelimab和RIS/erdafitinib[8]